A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression in adults with recurrent moderate-to-severe major depressive disorder (MDD) was evaluated. Patients (18–65 yr, N = 602) were randomized (1:1:1) to vortioxetine 10 or 20 mg/d or placebo for 8 wk in a double-b...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of neuropsychopharmacology 2014-10, Vol.17 (10), p.1557-1567
Main Authors: McIntyre, Roger S., Lophaven, Søren, Olsen, Christina K.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Analysis of Variance
Anti-Anxiety Agents - therapeutic use
Cognition & reasoning
Cognition Disorders - drug therapy
Cognition Disorders - etiology
Cognitive ability
Depression - complications
Depression - drug therapy
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
International Cooperation
Male
Middle Aged
Neuropsychological Tests
Piperazines - therapeutic use
Psychiatric Status Rating Scales
Sulfides - therapeutic use
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression in adults with recurrent moderate-to-severe major depressive disorder (MDD) was evaluated. Patients (18–65 yr, N = 602) were randomized (1:1:1) to vortioxetine 10 or 20 mg/d or placebo for 8 wk in a double-blind multi-national study. Cognitive function was assessed with objective neuropsychological tests of executive function, processing speed, attention and learning and memory, and a subjective cognitive measure. The primary outcome measure was change from baseline to week 8 in a composite z-score comprising the Digit Symbol Substitution Test (DSST) and Rey Auditory Verbal Learning Test (RAVLT) scores. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). In the pre-defined primary efficacy analysis, both doses of vortioxetine were significantly better than placebo, with mean treatment differences vs. placebo of 0.36 (vortioxetine 10 mg, p 
ISSN:1461-1457
1469-5111
DOI:10.1017/S1461145714000546